Skip to Content
Merck

Long-term outcome of children with congenital toxoplasmosis.

American journal of obstetrics and gynecology (2010-07-17)
Alain Berrébi, Corinne Assouline, Marie-Hélène Bessières, Myriam Lathière, Sophie Cassaing, Vincent Minville, Jean-Marc Ayoubi
ABSTRACT

Maternal toxoplasmosis infection acquired during pregnancy carries significant risk of fetal damage. We aimed to assess the long-term outcome of children and young adults with congenital toxoplasmosis diagnosed and treated in utero. This was a 20 year prospective study (1985-2005). All mothers received spiramycin, alone or associated with pyrimethamine-sulfadoxine, and underwent amniocentesis and monthly ultrasound screening. Infected children were followed every 3-6 months. Of 666 liveborn children (676 mothers), 112 (17%) had congenital toxoplasmosis. Among these, 107 were followed up for 12-250 months: 79 were asymptomatic (74%) and 28 had chorioretinitis (26%). Only 1 child had a serious neurological involvement. The percentage of chorioretinitis in treated children depends on length of follow-up, but this complication occurs mainly before the age of 5 years and almost always before the age of 10 years. Visual impairment was infrequently severe, and outcome appears consistently good. Long-term follow-up is recommended to monitor ocular and neurological prognosis, whatever the practical difficulties.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Spiramycin
Spiramycin, European Pharmacopoeia (EP) Reference Standard
Supelco
Spiramycin from Streptomyces sp., VETRANAL®, analytical standard, mixture of isomers